Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $36.40 USD
Change Today 0.00 / 0.00%
Volume 0.0
STDAF On Other Exchanges
As of 8:10 PM 04/15/15 All times are local (Market data is delayed by at least 15 minutes).

stada arzneimittel ag (STDAF) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/29/14 - $46.45
52 Week Low
01/5/15 - $30.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

stada arzneimittel ag (STDAF) Related Businessweek News

No Related Businessweek News Found

stada arzneimittel ag (STDAF) Details

STADA Arzneimittel AG engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. The company operates in two segments, Generics and Branded Products. The Generics segment provides various active ingredients, including stomach medicines, antihypertensive agents, and anti-inflammatory agents. This segment’s principal products include Omeprazole, a stomach medicine; Diclofenac, an antirheumatic drug; Tilidine, an opioid; Atorvastatin, an antilipemic; and Phospholipide, a liver medicine. The Branded Products segment offers non-prescription products. This segment primarily provides APO-go, a Parkinson medicine; Aqualor, a cold medicine based on seawater; Grippostad, a cold medicine; Snup, a nasal preparation; and Ladival, a sunscreen product. It serves patients and/or consumers, doctors, doctors’ cooperatives, pharmacies, pharmacy co-operatives, hospitals, wholesalers, and other service providers in the health care market, as well as public health insurance organizations or private insurances. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany.

10,363 Employees
Last Reported Date: 03/25/15
Founded in 1895

stada arzneimittel ag (STDAF) Top Compensated Officers

Chairman of The Executive Board
Total Annual Compensation: €2.8M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €1.1M
Chief Business Development & Central Services...
Total Annual Compensation: €1.1M
Compensation as of Fiscal Year 2014.

stada arzneimittel ag (STDAF) Key Developments

Stada-Arzneimittel Mulls Acquisitions

Stada-Arzneimittel AG (DB:SAZ) is seeking for acquisitions. Helmut Kraft, Chief Executive Officer of Stada-Arzneimittel said in full year 2014 Stada Arzneimittel AG earnings call, “It continues to allow us to make smaller bolt-on acquisitions with a focus on branded products once again and platforms being set up in the growth markets. And as you've seen through the slides the platforms are already there in each country. We just have to continue to supply them. So a steady flow of smaller product acquisitions preferably in the self-pay market, products in profitable, rapidly-growing niches is what we're aiming for. And products to round off our portfolio, a range expansion and different product categories, and, what we're really focusing on, the potential for products to be internationalized, or at least within a European setting, within our European subsidies.”

Stada-Arzneimittel Ag Reports Preliminary Group Earnings Results for the Year 2014; Provides Earnings guidance for 2015

Stada-Arzneimittel AG reported preliminary group earnings results for the year 2014. Group sales were €2,062.2 million against €2,003.9 million a year ago. Operating profit was €251.5 million against €202.1 million a year ago. Operating profit, adjusted was €306.3 million against €266.2 million a year ago. In 2014, reported operating profit decreased significantly by 24% to €188.5 million against €248.3 million a year ago, mainly due to impairments of goodwill in the market regions CIS/Eastern Europe as well as Asia/Pacific & MENA. EBITDA was €418.8 million against €382.6 million a year ago. EBITDA, adjusted was €431.9 million against €414.3 million a year ago. Net income was €64.6 million against €121.4 million a year ago. Net income, adjusted was €186.2 million against €160.6 million a year ago. Earnings per share were €1.07 against €2.04 a year ago. Earnings per share, adjusted were €3.08 against €2.70 a year ago. Cash flow from operating activities amounted to €223.8 million in the reporting year against €203.7 million a year ago. For the outlook for 2015, the Executive Board anticipates slight growth in Group sales adjusted for currency and portfolio effects. The Executive Board however expects a decreased earnings contribution from Russia due to the recent developments of the Russian ruble and increased risks in connection with consumer mood and the general market situation. Taking these developments into account and based on current currency relations, the Executive Board expects a substantial decrease in adjusted EBITDA and adjusted net income. The Executive Board expects the ratio of net debt excluding further acquisitions to adjusted EBITDA to be at a level of nearly 3 in 2015.

STADA AG Presents at HSBC's 13th Pan European Equity Conference, Apr-01-2015

STADA AG Presents at HSBC's 13th Pan European Equity Conference, Apr-01-2015 . Venue: HSBC France Offices, 109 Avenue des Champs-Elysees, Paris, France. Speakers: Alexander Groschke, Director IR, Scherwin Johannsen, Manager IR.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STDAF:US $36.40 USD 0.00

STDAF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.126.90 CHF +2.90
Hospira Inc $87.61 USD -0.05
Merck KGaA €104.97 EUR +0.86
Medicines Co/The $27.41 USD +0.09
UCB SA €69.02 EUR +0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation STDAF Industry Range
Price/Earnings 29.0x
Price/Sales 0.9x
Price/Book 2.2x
Price/Cash Flow 28.8x
TEV/Sales 0.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STADA ARZNEIMITTEL AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at